JP2006512339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512339A5 JP2006512339A5 JP2004560887A JP2004560887A JP2006512339A5 JP 2006512339 A5 JP2006512339 A5 JP 2006512339A5 JP 2004560887 A JP2004560887 A JP 2004560887A JP 2004560887 A JP2004560887 A JP 2004560887A JP 2006512339 A5 JP2006512339 A5 JP 2006512339A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- optionally
- nitrogen
- saturated
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 33
- 229920006395 saturated elastomer Polymers 0.000 claims 20
- 229910052757 nitrogen Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 11
- 229910052698 phosphorus Inorganic materials 0.000 claims 11
- 239000011574 phosphorus Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010035148 Plague Diseases 0.000 claims 3
- 241000607479 Yersinia pestis Species 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43337802P | 2002-12-13 | 2002-12-13 | |
| PCT/US2003/039975 WO2004055012A1 (en) | 2002-12-13 | 2003-12-12 | Indane compounds as ccr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006512339A JP2006512339A (ja) | 2006-04-13 |
| JP2006512339A5 true JP2006512339A5 (enExample) | 2007-01-11 |
Family
ID=32595172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560887A Pending JP2006512339A (ja) | 2002-12-13 | 2003-12-12 | Ｃｃｒ５アンタゴニストとしてのインダン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7531661B2 (enExample) |
| EP (1) | EP1581530A1 (enExample) |
| JP (1) | JP2006512339A (enExample) |
| AU (1) | AU2003300952A1 (enExample) |
| WO (1) | WO2004055012A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006017468A2 (en) | 2004-08-02 | 2006-02-16 | Glaxo Group Limited | Antibacterial agents |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| EA201100114A1 (ru) | 2008-08-11 | 2011-10-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| KR101616396B1 (ko) | 2008-08-11 | 2016-04-28 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
| EA021048B1 (ru) | 2010-02-10 | 2015-03-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| US9439424B2 (en) | 2012-09-28 | 2016-09-13 | Dow Agrosciences Llc | Synergistic weed control from applications of aminocyclopyrachlor and aminopyralid |
| US10412964B2 (en) | 2012-12-14 | 2019-09-17 | Dow Agrosciences Llc | Synergistic weed control from applications of aminopyralid and clopyralid |
| EP2931045B1 (en) | 2012-12-14 | 2018-12-26 | Dow AgroSciences LLC | Synergistic weed control from applications of aminopyralid and clopyralid |
| JP6452711B2 (ja) | 2014-02-20 | 2019-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体 |
| JP2017533925A (ja) | 2014-11-13 | 2017-11-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体 |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN109593089B (zh) * | 2019-01-24 | 2022-01-28 | 西南大学 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
| CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
| CN114391015A (zh) | 2019-05-16 | 2022-04-22 | 斯汀塞拉股份有限公司 | 苯并[b][1,8]萘啶乙酸衍生物和使用方法 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000010965A2 (en) * | 1998-08-20 | 2000-03-02 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use as anti-hiv agents |
| JP2001058988A (ja) * | 1998-12-21 | 2001-03-06 | Takeda Chem Ind Ltd | アニリド誘導体、その製造法および用途 |
| JP2001058992A (ja) * | 1999-06-16 | 2001-03-06 | Takeda Chem Ind Ltd | ベンゾアゼピン誘導体、その製造法および用途 |
| CA2393757C (en) * | 1999-12-08 | 2009-04-07 | Teijin Limited | Cycloamine ccr5 receptor antagonists |
| KR100503161B1 (ko) * | 2002-07-18 | 2005-07-25 | 한미약품 주식회사 | 신규한 ｐ-당단백질 저해제, 그의 제조방법 및 이를유효성분으로 하는 경구투여용 조성물 |
-
2003
- 2003-12-12 JP JP2004560887A patent/JP2006512339A/ja active Pending
- 2003-12-12 AU AU2003300952A patent/AU2003300952A1/en not_active Abandoned
- 2003-12-12 WO PCT/US2003/039975 patent/WO2004055012A1/en not_active Ceased
- 2003-12-12 US US10/538,183 patent/US7531661B2/en not_active Expired - Fee Related
- 2003-12-12 EP EP03813460A patent/EP1581530A1/en not_active Withdrawn
-
2009
- 2009-04-01 US US12/416,178 patent/US7589204B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512339A5 (enExample) | ||
| JP2006514950A5 (enExample) | ||
| JP2006511555A5 (enExample) | ||
| JP2002543185A5 (enExample) | ||
| CN102239164B (zh) | 2h-色烯化合物及其衍生物 | |
| RU2006144709A (ru) | Земещенные 2-хинолилоксазолы, пригодные в качестве ингибиторы фдэ4 | |
| JP2020537657A5 (enExample) | ||
| ZA200603474B (en) | Alkoxy substituted imidazoquinolines | |
| JP2006511552A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2018507238A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| JP2010508296A5 (enExample) | ||
| RU2003105885A (ru) | Ингибиторы клеточной адгезии, опосредованной альфа 4-интегринами | |
| JP2010536887A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| JP2011523412A5 (enExample) | ||
| JP2010500293A5 (enExample) | ||
| JP2017504650A5 (enExample) | ||
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| RU2008134534A (ru) | 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2007522142A5 (enExample) |